Mon, Nov 07, 2022
Divis lab share price: The stock was at its 52-week low at Rs 3488.80 per share. On both the indices between 12:52 pm to 12:55 pm from around Rs 3,600 apiece and to Rs 3,400 apiece.
More >
Wed, May 25, 2022
The Indian market closed with half per cent cuts on Tuesday as it extended losing streak to secondary day amid volatility and inflation fears.
Mon, Feb 08, 2021
Divi’s Laboratories reported in-line Q3 FY21 earnings. This was led by healthy traction in Generics / Custom Synthesis (CS), coupled with lower raw material cost, driven by process improvements. Meaningful benefit is yet to accrue from the major capex phase. 10 new molecules under development in generic APIs and contrast media APIs would provide a fillip going forward.
Mon, Dec 07, 2020
Divi's Laboratories is one of the leading manufacturers of Active Pharmaceutical Ingredients (API) in the world. Growth prospects of Divi’s look decent with favorable traits in the API industry due to supply chain readjustments/ diversification from China into other countries including India amid the COVID-19 pandemic. As global players are looking to reduce dependency on China and preferring India, companies like Divi’s remain well placed to capitalize on such opportunities. Also, in custom synthesis, the company is connected with several pharma giants and looks to benefit as India may tap opportunities in terms of the consumption of custom synthesis.
Sat, Feb 04, 2017
Updating on US-FDA inspection, Divi's Lab said, "It has filed its comprehensive response to the observations of the FDA regulator within the stipulated time. Now it awaits for review from the US pharma regulator.
Mon, Dec 26, 2016
Pharmaceutical major Divi's Laboratories Ltd continued to fall on Monday with the stock cracking over 10%, or Rs 85.75 per share.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
